Edotreotide

From Wikipedia, the free encyclopedia
  (Redirected from Yttrium Y 90-DOTA-tyr3-octreotide)
Jump to navigation Jump to search
Edotreotide
Edotreotide.svg
Names
IUPAC name
2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(2R,3R)-1,3-dihydroxybutan-2-yl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-7,10-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid
Identifiers
3D model (JSmol)
ChemSpider
UNII
Properties
C65H92N14O18S2
Molar mass 1421.65 g·mol−1
Pharmacology
License data
Pharmacology
Legal status
  • EU: Rx-only [1]
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)
Infobox references

Edotreotide (USAN, also known as (DOTA0-Phe1-Tyr3)octreotide, or DOTATOC) is a substance which, when bound to various radionuclides, is used in the treatment and diagnosis of certain types of cancer.[2] When used therapeutically it is an example of peptide receptor radionuclide therapy.

Yttrium-90[edit]

A phase 1 clinical trial of yttrium-90 labelled edotreotide concluded in 2011,[3] aiming to investigated effects in young cancer patients (up to 25 years of age). Specific cancers being included in the trial include neuroblastoma, childhood brain tumours and gastrointestinal cancer.[4]

A phase 2 trial for the use of 90Y DOTA-TOC for patients with metastatic carcinoid, where octreotide treatment was no longer effective, also reported results in 2010.[5]

Yttrium-90 labeled edotreotide

Lutetium-177[edit]

Lutetium-177 labelled edotreotide (177Lu-DOTA-TOC), with the trade name Solucin, is the subject of a phase 3 clinical trial for treatment of GEP-NETs.[6][7] It was granted orphan drug designation by the European Medicines Agency in 2014.[8]

See also[edit]

References[edit]

  1. ^ "SomaKit TOC EPAR". European Medicines Agency (EMA). Retrieved 20 October 2020.
  2. ^ Martindale, The Extra Pharmacopoeia, 30th ed, p1161.
  3. ^ "Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors". ClinicalTrials.gov. US National Library of Medicine. Retrieved 7 November 2020.
  4. ^ Menda Y, O'Dorisio MS, Kao S, Khanna G, Michael S, Connolly M, et al. (October 2010). "Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors". Journal of Nuclear Medicine. 51 (10): 1524–31. doi:10.2967/jnumed.110.075226. PMC 3753801. PMID 20847174.
  5. ^ Bushnell DL, O'Dorisio TM, O'Dorisio MS, Menda Y, Hicks RJ, Van Cutsem E, et al. (April 2010). "90Y-edotreotide for metastatic carcinoid refractory to octreotide". Journal of Clinical Oncology. 28 (10): 1652–9. doi:10.1200/JCO.2009.22.8585. PMC 4872330. PMID 20194865.
  6. ^ "The therapeutic n.c.a. 177Lu-Edotreotide (Solucin)". ITM Isotopen Technologien München AG. Retrieved 7 November 2020.
  7. ^ "A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium 177-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET)". EU Clinical Trials Register. Retrieved 7 November 2020.
  8. ^ "EU/03/14/1269". European Medicines Agency. Retrieved 7 November 2020.

External links[edit]

  • "Edotreotide". Drug Information Portal. U.S. National Library of Medicine.